Comparison of Efficacy of Different Criteria for Repeated Drug Injections of Ranibizumab in the Treatment of Macular Edema Secondary to Retinal Branch Vein Occlusion
Objective:To investigate the efficacy of different criteria for repeated drug injections of Ranibizumab in the treatment of macular edema secondary to retinal branch vein occlusion.Method:A total of 60 patients(60 eyes)diagnosed with macular edema secondary to retinal branch vein occlusion were selected from July 2020 to July 2022 in the Ophthalmology Department of Nanxishan Hospital of Guangxi Zhuang Autonomous Region.All patients were treated with intravitreal injection of Ranibizumab.A prospective randomized controlled study was conducted,and patients were randomly divided into experimental group(n=30)and control group(n=30)according to the random number method.In the experimental group,the repeated drug injections was the central macular thickness(CMT)>250 μm or the presence of foveal or parafoveal edema(strict criteria for repeated drug injections).In the control group,the repeated drug injections was CMT>300 μm,which was significantly thicker than the last follow-up,and the visual acuity decreased by more than 1 line(looser criteria for repeated drug injections).Both groups were followed up for six months,once a month.The average number of injections,best corrected visual acuity(BCVA),CMT before and after treatment and the incidence of complications were observed.Result:The average injection frequency of the experimental group was significantly higher than that of the control group,the difference was statistically significant(P<0.05).There was no significant difference in value of BCVA between the two groups before treatment(P>0.05).Compared with BCVA of before treatment,the values of BCVA of the experimental group were significantly increased at different treatment times,while the values of BCVA of the control group were significantly increased at 4 months,5 months and 6 months,the differences were statistically significant(P<0.05).The values of BCVA of the experimental group at 2 months,3 months,4 months,5 months and 6 months after treatment were significantly higher than those of the control group,the differences were statistically significant(P<0.05).There was no significant difference in CMT between the two groups before treatment(P>0.05).Compared with the value of CMT of before treatment,the values of CMT of the two groups were significantly decreased at different treatment times,and values of the CMT of the experimental group were significantly lower than those of the control group,the differences were statistically significant(P<0.05).There were no ocular or non-ocular complications associated with Ranibizumab injection in either group during the study period.Conclusion:Looser criteria for repeated drug injections of Ranibizumab can significantly reduce the macular edema secondary to retinal branch vein occlusion patients'number of repeated infusion during follow-up,and strict criteria for repeated drug injections are more conducive to the improvement of BCVA and CMT.In clinical practice,it should be selected according to the specific conditions of patients.
RanibizumabCriteria for repeated drug injectionsRetinal branch vein occlusionMacular edema
国家科技期刊平台
NSTL
万方数据
